Arkolith/Insider Trading/NKGN/Form 4

Song Paul Y.

Chief Executive OfficerNKGen Biotech, Inc. (NKGN) · full profile →Form 4 · filed May 7, 2025
Net Buying
Open-Market Buys
$2.7M
Open-Market Sells
$0
Net Open-Market Flow
$2.7M
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 5, 2025Buy(P)20.8M$0.13$2.7M21.0M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 5, 2025Buy(P)41.7M$0.13$5.4M41.7M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-25-040627) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML